Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry.
Khava I E IbragimovaSandra M E GeurtsSander CroesFrans ErdkampJoan B HeijnsJolien TolBirgit E P J VriensKirsten N A AalderingMarcus W DercksenManon J A E PepelsNatascha A J B PetersLinda van de WinkelDominique J P TilliIngeborg J H VriensMaaike de BoerVivianne C G Tjan-HeijnenPublished in: Breast cancer research and treatment (2021)
The survival of patients with HER2 + ABC improved since the introduction of pertuzumab and T-DM1. There is room for improvement in implementation of these HER2-targeted therapies, especially in patients with HR + /HER2 + disease.